Last reviewed · How we verify
Olumiant (baricitinib)
At a glance
| Generic name | baricitinib |
|---|---|
| Sponsor | Eli Lilly |
| Drug class | Janus Kinase Inhibitor [EPC] |
| Target | Tyrosine-protein kinase JAK2 |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2018 |
| Annual revenue | 1200 |
Approved indications
- Alopecia areata
- Atopic dermatitis
- Pneumonia caused by Severe acute respiratory syndrome coronavirus 2
- Rheumatoid arthritis
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Urinary tract infection
- Headache
- Back pain
- Glomerular filtration rate decreased
- Bronchitis
- Arthralgia
- Anaemia
- Hypertension
- Lymphocyte count decreased
- Diarrhoea
Key clinical trials
- A Study in Moderate to Severe Rheumatoid Arthritis Participants (PHASE3)
- A Moderate to Severe Rheumatoid Arthritis Study (PHASE3)
- A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy (PHASE2)
- Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy (PHASE2)
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis (PHASE1)
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (PHASE3)
- A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) (PHASE3)
- Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olumiant CI brief — competitive landscape report
- Olumiant updates RSS · CI watch RSS
- Eli Lilly portfolio CI